Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.

Abstract

The present study confirms the clinical efficacy of omalizumab in patients with severe allergic asthma irrespective of age in a real-life setting outside the omalizumab trial program.

Full Text

• DOI - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (DOI)
• Ovid Technologies, Inc. - full-text online
• OhioLINK Electronic Journal Center - full-text online
• Elsevier Science - full-text online
• EBSCO - full-text online

Subjects

• Adolescent
• Adult
• Age Factors
• Aged
• Anti-Asthmatic Agents
• Antibodies, Monoclonal
• Asthma
• Child
• Disease Progression
• Female
• Follow-Up Studies
• Germany
• Humans
• Immunoglobulin E
• Male
• Middle Aged
• Product Surveillance, Postmarketing
• Respiratory Function Tests

Similar articles

• Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma. (2013-05-09)
• A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland. (2013-04-02)
• Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. (2013-03-15)
• A proof of concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma. (2013-04-11)
• Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma. (2013-03-19)
• Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients. (2006-10-17)
• Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy. (2012-08-24)
• Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. (2012-10-18)
• The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology. (2012-11-05)
• Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. (2006-02-27)

Authors

• Stephanie Korn
• Christian Schumann
• Cornelia Kropf
• Kathrin Stoiber
• Antje Thielen
• Christian Taube
• Roland Buhl

Publication date

2010-10-11

Journal

Journal topics

• Asthma
• Hypersensitivity
• Immunity

Language

Eng.

Copyright

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Pulmonary Department, Mainz University Hospital, Mainz, Germany. Stephanie.Korn [at] unimedizin-mainz.de

Release reference

Ann Allergy Asthma Immunol. 2010 Oct;105(4):313-9

Related books

• Books of Age Factors
• Books of Anti-Asthmatic Agents
• Books of Antibodies, Monoclonal
• Books of Asthma
• Books of Asthma
• Books of Disease Progression
• Books of Follow-Up Studies
• Books of Germany
• Books of Hypersensitivity
• Books of Immunity
• Books of Immunoglobulin E
• Books of Product Surveillance, Postmarketing
• Books of Respiratory Function Tests